• 1
    Brautbar, A. and Ballantyne, C. M., Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nat. Rev. Cardiol. 2011. 8: 253265.
  • 2
    Khovidhunkit, W., Kim, M. S., Memon, R. A., Shigenaga, J. K., Moser, A. H., Feingold, K. R. and Grunfeld, C., Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res. 2004. 45: 11691196.
  • 3
    David, M. Z. and Daum, R. S., Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin. Microbiol. Rev. 2010. 23: 616687.
  • 4
    Morath, S., Geyer, A. and Hartung, T., Structure-function relationship of cytokine induction by lipoteichoic acid from Staphylococcus aureus. J. Exp. Med. 2001. 193: 393397.
  • 5
    Bubeck Wardenburg, J., Williams, W. A. and Missiakas, D., Host defenses against Staphylococcus aureus infection require recognition of bacterial lipoproteins. Proc. Natl. Acad. Sci. USA 2006. 103: 1383113836.
  • 6
    Kang, J. Y., Nan, X., Jin, M. S., Youn, S. J., Ryu, Y. H., Mah, S., Han, S. H. et al., Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity 2009. 31: 873884.
  • 7
    Takeuchi, O., Hoshino, K. and Akira, S., Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J. Immunol. 2000. 165: 53925396.
  • 8
    Hoebe, K., Georgel, P., Rutschmann, S., Du, X., Mudd, S., Crozat, K., Sovath, S. et al., CD36 is a sensor of diacylglycerides. Nature 2005. 433: 523527.
  • 9
    Schroder, N. W., Morath, S., Alexander, C., Hamann, L., Hartung, T., Zahringer, U., Gobel U.B. et al., Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J. Biol. Chem. 2003. 278: 1558715594.
  • 10
    Barcia, A. M. and Harris, H. W., Triglyceride-rich lipoproteins as agents of innate immunity. Clin. Infect. Dis. 2005. 41 Suppl 7: S498S503.
  • 11
    Feingold, K. R. and Grunfeld, C., The role of HDL in innate immunity. J. Lipid Res. 2011. 52: 13.
  • 12
    Peterson, M. M., Mack, J. L., Hall, P. R., Alsup, A. A., Alexander, S. M., Sully, E. K., Sawires, Y. S. et al., Apolipoprotein B is an innate barrier against invasive Staphylococcus aureus infection. Cell. Host Microbe. 2008. 4: 555566.
  • 13
    Bhakdi, S., Tranum-Jensen, J., Utermann, G. and Fussle, R., Binding and partial inactivation of Staphylococcus aureus alpha-toxin by human plasma low density lipoprotein. J. Biol. Chem. 1983. 258: 58995904.
  • 14
    Grunfeld, C., Marshall, M., Shigenaga, J. K., Moser, A. H., Tobias, P. and Feingold, K. R., Lipoproteins inhibit macrophage activation by lipoteichoic acid. J. Lipid Res. 1999. 40: 245252.
  • 15
    Mueller, M., Stamme, C., Draing, C., Hartung, T., Seydel, U. and Schromm, A. B., Cell activation of human macrophages by lipoteichoic acid is strongly attenuated by lipopolysaccharide-binding protein. J. Biol. Chem. 2006. 281: 3144831456.
  • 16
    Knapp, S., von Aulock, S., Leendertse, M., Haslinger, I., Draing, C., Golenbock, D. T. and van der Poll, T., Lipoteichoic acid-induced lung inflammation depends on TLR2 and the concerted action of TLR4 and the platelet-activating factor receptor. J. Immunol. 2008. 180: 34783484.
  • 17
    Hashimoto, M., Furuyashiki, M., Kaseya, R., Fukada, Y., Akimaru, M., Aoyama, K., Okuno, T. et al., Evidence of immunostimulating lipoprotein existing in the natural lipoteichoic acid fraction. Infect Immun. 2007. 75: 19261932.
  • 18
    Stoll, H., Dengjel, J., Nerz, C. and Gotz, F., Staphylococcus aureus deficient in lipidation of prelipoproteins is attenuated in growth and immune activation. Infect. Immun. 2005. 73: 24112423.
  • 19
    Bunk, S., Sigel, S., Metzdorf, D., Sharif, O., Triantafilou, K., Triantafilou, M., Hartung, T. et al., Internalization and coreceptor expression are critical for TLR2-mediated recognition of lipoteichoic acid in human peripheral blood. J. Immunol. 2010. 185: 37083717.
  • 20
    Levels, J. H., Abraham, P. R., van Barreveld, E. P., Meijers, J. C. and van Deventer, S. J., Distribution and kinetics of lipoprotein-bound lipoteichoic acid. Infect. Immun. 2003. 71: 32803284.
  • 21
    Segrest, J. P., Jones, M. K., De Loof, H. and Dashti, N., Structure of apolipoprotein B-100 in low density lipoproteins. J. Lipid Res. 2001. 42: 13461367.
  • 22
    Shor, R., Wainstein, J., Oz, D., Boaz, M., Matas, Z., Fux, A. and Halabe, A., Low serum LDL cholesterol levels and the risk of fever, sepsis, and malignancy. Ann. Clin. Lab. Sci. 2007. 37: 343348.
  • 23
    Ginsburg, I., Role of lipoteichoic acid in infection and inflammation. Lancet. Infect. Dis. 2002. 2: 171179.
  • 24
    Ishibashi, S., Brown, M. S., Goldstein, J. L., Gerard, R. D., Hammer, R. E. and Herz, J., Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 1993. 92: 883893.
  • 25
    Netea, M. G., Demacker, P. N., Kullberg, B. J., Boerman, O. C., Verschueren, I., Stalenhoef, A. F. and van der Meer, J. W., Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections. J. Clin. Invest. 1996. 97: 13661372.
  • 26
    Jiao, Y. L. and Wu, M. P., Apolipoprotein A-I diminishes acute lung injury and sepsis in mice induced by lipoteichoic acid. Cytokine 2008. 43: 8387.
  • 27
    Morath, S., Geyer, A., Spreitzer, I., Hermann, C. and Hartung, T., Structural decomposition and heterogeneity of commercial lipoteichoic acid preparations. Infect. Immun. 2002. 70: 938944.
  • 28
    Bartolome, N., Arteta, B., Martinez, M. J., Chico, Y. and Ochoa, B., Kupffer cell products and interleukin 1beta directly promote VLDL secretion and apoB mRNA up-regulation in rodent hepatocytes. Innate Immun. 2008. 14: 255266.
  • 29
    Bartolome, N., Rodriguez, L., Martinez, M. J., Ochoa, B. and Chico, Y., Upregulation of apolipoprotein B secretion, but not lipid, by tumor necrosis factor-alpha in rat hepatocyte cultures in the absence of extracellular fatty acids. Ann. NY Acad. Sci. 2007. 1096: 5569.
  • 30
    Draing, C., Traub, S., Deininger, S., Mang, P., Moller, H. M., Manso, M., Rossi, F. et al., Polypropylene glycol is a selective binding inhibitor for LTA and other structurally related TLR2 agonists. Eur. J. Immunol. 2008. 38: 797808.
  • 31
    Thompson, G. R., Catapano, A., Saheb, S., Atassi-Dumont, M., Barbir, M., Eriksson, M., Paulweber, B. et al., Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. Curr. Opin. Lipidol. 2010. 21: 492498.